Port Charlotte, FL3 Active Studies

Myasthenia Gravis Clinical Trials in Port Charlotte, FL

Find 3 actively recruiting myasthenia gravis clinical trials in Port Charlotte, FL. Connect with local research sites and explore new treatment options.

3
Active Trials
3
Sponsors
441
Enrolling

Recruiting Myasthenia Gravis Studies in Port Charlotte

About Myasthenia Gravis Clinical Trials in Port Charlotte

Myasthenia gravis is a chronic autoimmune neuromuscular disease that causes weakness in the skeletal muscles responsible for breathing and movement. It occurs when communication between nerves and muscles is disrupted. Treatment includes medications that improve neuromuscular transmission and immunosuppressive therapies.

There are currently 3 myasthenia gravis clinical trials recruiting participants in Port Charlotte, FL. These studies are seeking a combined 441 participants. Research is being sponsored by Immunovant Sciences GmbH, RemeGen Co., Ltd., argenx. Clinical trial participation is free and participants receive study-related medical care at no cost.

Myasthenia Gravis Clinical Trials in Port Charlotte — FAQ

Are there myasthenia gravis clinical trials in Port Charlotte?

Yes, there are 3 myasthenia gravis clinical trials currently recruiting in Port Charlotte, FL. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Port Charlotte?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Port Charlotte research site will contact you about next steps.

Are clinical trials in Port Charlotte free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Port Charlotte studies also compensate for your time and travel.

What myasthenia gravis treatments are being tested?

The 3 active trials in Port Charlotte are testing new therapies including novel drugs, biologics, and treatment approaches for myasthenia gravis.

Data updated March 2, 2026 from ClinicalTrials.gov